Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Crispr Therapeutics AG (CRSP)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Crispr Therapeutics's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
53.15 -1.68    -3.06%
19:31:30 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 587,288
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 52.98 - 54.44
Type:  Equity
Market:  United States
Crispr Therapeutics 53.15 -1.68 -3.06%

NASDAQ:CRSP Financials

 
This summary provides an overview of the most significant critical numbers from each of the Crispr Therapeutics AG financial reports, including theCrispr Therapeutics AG income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the NASDAQ:CRSP financials over time via breakdowns of their annual reports.

CRISPR Therapeutics AG reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 371.21 million compared to USD 1.2 million a year ago. Net loss was USD 153.61 million compared to USD 650.18 million a year ago. Basic loss per share from continuing operations was USD 1.94 compared to USD 8.36 a year ago. Diluted loss per share from continuing operations was USD 1.94 compared to USD 8.36 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

CRSP Income Statement & Profits

Gross margin TTM -39.43%
Operating margin TTM -59.95%
Net Profit margin TTM -41.38%
Return on Investment TTM -9.66%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 201.21 70 100
Gross Profit 86.06 -114.12 -76.19 -42.13
Operating Income 69.58 -132.41 -95.22 -64.49
Net Income 89.35 -112.15 -77.74 -53.06

CRSP Balance Sheet

Quick Ratio MRQ 17.41
Current Ratio MRQ 17.54
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 12.67%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 2229.57 2086.83 2197.01 2244.36
Total Liabilities 346.77 359.04 380.99 389.47
Total Equity 1882.8 1727.79 1816.03 1854.9

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM -3.28
Revenue/Share TTM 4.67
Operating Cash Flow  -88.31%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -96.07 -39.86 -133.24 8.8
Cash From Investing Activities -81.45 121.35 216.92 117.83
Cash From Financing Activities 38.94 1.56 16.76 5.4
Net Change in Cash -138.53 83 100.47 132.06
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

CRSP Price Commentary

Write your thoughts about Crispr Therapeutics AG
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
SirRichard TheFirst
SirRichard TheFirst Jun 29, 2023 13:57
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is It going to 0 or 290?
Reply
0 0
Report
Ken Laing
Ken Laing Nov 19, 2021 9:19
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Good time to get in now
Reply
3 0
Report
Alex Ge
Alex Ge Sep 01, 2021 16:03
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Crispr is a long term gamble. If they deliver on the innovations promised, they could potentially become massive. If not, then 💀
Reply
6 2
Report
Oc Masai
Oc Masai Jun 28, 2021 12:01
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Very bullish thanks you
Reply
5 0
Report
Ken Laing
Ken Laing Mar 28, 2021 13:11
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://tickeron.com/news/10211746-crispr-therapeutics-ag-s-crsp-111-24-moving-average-convergence-divergence-macd-histogram-just-turned-negative
Reply
0 0
Report
Ken Laing
Ken Laing Mar 28, 2021 13:11
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Glad I got out at 124, will be buying back around 80s
Reply
1 1
Report
Charlie palmer
Charlie palmer Mar 26, 2021 19:12
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
even better price now the future is bright think 5 years time
Reply
3 0
Report
Ken Laing
Ken Laing Mar 24, 2021 16:42
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This is going back to 100
Reply
0 2
Report
Ahmad Mujadid
Ahmad Mujadid Mar 24, 2021 16:42
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
then we should all in if its down to 100
Reply
0 0
Report
Ken Laing
Ken Laing Mar 24, 2021 16:42
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ahmad Mujadid are you all in yet?
Reply
0 0
Report
Charlie palmer
Charlie palmer Mar 02, 2021 14:10
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
excellent time to buy at this price
Reply
5 2
Report
Charalampos Kouletakis
Charalampos Kouletakis Jan 29, 2021 19:16
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
decent entry levels around the current price ~160
Reply
7 2
Report
James Thomas
James Thomas Dec 29, 2020 23:28
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Do anyone know why Crispr down today? I noticed the Ark related biotech having a serious *****did Ark relasing their shares?
Reply
0 1
Report
Randall Sta Maria
Randall Sta Maria Dec 29, 2020 23:28
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Biotech was down because one of ark largest holding Arcturus dropped 50%. So its just a spill over effect shock to the other biotechs in Arks portfolio. Nothing to do with Crispr fundamentals. So its a ******good buying opportunity
Reply
4 1
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email